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A B S T R A C T
Background
Paraquat is an effective and widely used herbicide but is also a lethal poison. In many developing countries paraquat is widely available
and inexpensive, making poisoning prevention difficult. However most of the people who become poisoned from paraquat have taken
it as a means of suicide.
Standard treatment for paraquat poisoning both prevents further absorption and reduces the load of paraquat in the blood through
haemoperfusion or haemodialysis. The effectiveness of standard treatments is extremely limited.
The immune system plays an important role in exacerbating paraquat-induced lung fibrosis. Immunosuppressive treatment using
glucocorticoid and cyclophosphamide in combination is being developed and studied.
Objectives
To assess the effects of glucocorticoid with cyclophosphamide on mortality in patients with paraquat-induced lung fibrosis.
Search methods
To identify randomised controlled trials on this topic, we searched the Cochrane Injuries Group’s Specialised Register (searched 15 Sept
2009), CENTRAL (The Cochrane Library 2009, Issue 3), MEDLINE (Ovid SP) (1950 SeptemberWeek 1 2009), EMBASE (Ovid SP)
(1980 to 2009 Week 37), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to Sept 2009), ISI Web of
Science: Conference Proceedings Citation Index - Science (CPCI-S) (1990 to Sept 2009), Chinese bio-medical literature & retrieval
system (CBM) (1978 to Sept 2009), Chinese medical current contents (CMCC) (1995 to Sept 2009), and Chinese medical academic
conference (CMAC) (1994-Sept 2009). The searches were completed in September 2009.
Selection criteria
Randomised controlled trials (RCTs) were included in this review. All patients were to receive standard care, plus the intervention or
control. The intervention was glucocorticoid with cyclophosphamide in combination versus a control of a placebo, standard care alone,
or any other therapy in addition to standard care.
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Data collection and analysis
The mortality risk ratio (RR) and 95% confidence interval (CI) was calculated for each study on an intention-to-treat basis. Data for
all-cause mortality at final follow-up were summarised in a meta-analysis using a fixed-effects model.
Main results
This systematic review includes three trials with a combined total of 164 participants who had moderate to severe paraquat poisoning.
Patients who received glucocorticoid with cyclophosphamide in addition to standard care had a lower risk of death at final follow-up
than those receiving standard care only (RR 0.72 (95% CI 0.59 to 0.89)).
Authors’ conclusions
Based on the findings of three small RCTs of moderate to severely poisoned patients, glucocorticoid with cyclophosphamide in addition
to standard care may be a beneficial treatment for patients with paraquat-induced lung fibrosis. To enable further study of the effects of
glucocorticoid with cyclophosphamide for patients with moderate to severe paraquat poisoning, hospitals may provide this treatment
as part of an RCT with allocation concealment.
P L A I N L A N G U A G E S U M M A R Y
Using steroids and cyclophosphamide together may reduce deaths from paraquat poisoning
Paraquat is an effective and widely used herbicide but is also a lethal poison. In many developing countries paraquat is widely available
and inexpensive, making poisoning prevention difficult. However most of the people who become poisoned from paraquat have taken
it as a means of suicide.
Standard care for removing paraquat from the body involves vomiting, consuming activated charcoal or Fuller’s Earth (which absorbs
paraquat), and blood filtering. This review aims to assess the effects of giving patients steroids and cyclophosphamide in addition to
standard care to prevent death after paraquat poisoning.
We found three small randomised controlled trials in which patients with moderate or severe poisoning were given either standard
care only or standard care and steroids and cyclophosphamide. When the results of the three studies were combined, we found that
patients who were given standard care and steroids and cyclophosphamide had a reduced risk of death of about 28% (statistically
estimated range from 41% to 11%) compared with patients given standard care alone. However, the studies were small and one was
of low methodological quality so this finding should be interpreted with caution. To better understand the effects of this intervention
for poisoned patients, we recommend treatment be given in the context of a randomised controlled trial so that future results can be
analysed with similar studies.
B A C K G R O U N D
Paraquat is one of the most widely used herbicides worldwide.
It is commercially produced and has been sold in around 130
countries since 1961, despite its fatal toxicity to humans (Tomlin
1994). Because it is inexpensive and widely available, it is difficult
to prevent paraquat poisoning. Paraquat poisoning by accidental
or voluntary ingestion accounts for numerous deaths each year,
predominantly in developing countries where its use is less strin-
gently controlled than in Europe or the United States.
An epidemiologic study of poisoning in rural Sri Lanka found
an incidence of poisoning of 75 per 100,000 population, with a
death rate up to 22 per 100,000 population. The incidence and
death rates from poisoning were highest in the 15-34 age group,
and there were significant differences in the incidence of poisoning
among different ethnic groups. In this study, paraquat was the
most common poisoning agent (Hettiarachchi 1989).
In China, paraquat poisoned patients are usually women and chil-
dren in impoverished rural areas, who are not well-educated and
are often unfairly treated. In many cases, the decision to drink
paraquat is impulsive and follows an intense interpersonal conflict
(Wang 2008).
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Description of the condition
The prognosis in paraquat poisoning is associatedwith the amount
of toxin ingested:
• In low dose poisoning (<20 mg of paraquat ion per kg of
body weight) patients are often asymptomatic, or may develop
vomiting or diarrhoea, but have a good chance of recovery.
• In moderate dose poisoning patients (20 to 40 mg of
paraquat ion per kg of body weight), initial renal and hepatic
dysfunction is common. Mucosal damage may become apparent
with sloughing of the mucous membranes in the mouth.
Difficulty in breathing may develop after a few days in the more
severe cases. After about 10 days, although renal function often
returns to normal, radiological signs of lung damage usually
develop. Lung damage is usually followed by irreversible massive
pulmonary fibrosis manifested by the progressive loss of the
lungs’ ability to breathe, and deterioration continues until the
patient eventually dies, between 2 to 4 weeks after ingestion.
• In high dose poisoning patients (>40 mg paraquat ion per
kg of body weight), toxicity is much more severe and death
occurs early (within 24-48 hrs) from multiple organ failure.
Vomiting and diarrhoea are severe, with considerable fluid loss.
Renal failure, cardiac arrhythmias, coma, convulsions, and
oesophageal perforation leads to death (WHO 2009).
Description of the intervention
The care of a paraquat poisoned person involves reducing the
quantity of paraquat ingested and removing paraquat from the
bloodstream. Vomiting should be induced as soon as possible to
prevent further absorption of the toxin (Dinham 1996). Upon
arrival at the emergency room, further interventions may include
gastric aspiration, gastric lavage, repeated administration of the ab-
sorbents activated charcoal or Fuller’s Earth, and purgatives such as
mannitol or sorbitol (WHO 2009). Haemodialysis, haemofiltra-
tion, and haemoperfusion could be instituted in the aim to reduce
the load of poison in the blood, but these interventions have no
proven effects for improving survival (Suzuki 1993; Koo 2002),
mainly because paraquat accumulates in the lungs.
Paraquat molecules selectively accumulate in the lungs, leading to
irreversible pulmonary fibrosis which is also known as ’paraquat
lung’ (Smith 1975; Fukuda 1985). This accumulation process be-
gins immediately after ingestion and lasts from 2 to 4 weeks. A
large proportion of patients appear asymptomatic until signs of
breathing difficulty emerge; it is difficult to predict the outcome of
a patient who appears normal but is actually suffering lung fibrosis
(Eddleston 2003).
While numerousmethods are available to reduce paraquat concen-
tration in the blood stream, the progression of lung injury through
the deposited paraquat is a major concern. The combination of
glucocorticoid combined with cyclophosphamide as a means of
suppressing the immunoreactions which cause lung damage has
been tested since the 1970s (Eddleston 2003), but the effective-
ness of this treatment is unknown. The timing of providing treat-
ment, the duration of treatment, and the dosage of drugs can vary
depending on the needs of the patient.
How the intervention might work
After being actively accumulated by lung cells, paraquat cataly-
ses the formation of certain chemicals, namely superoxide, singlet
oxygen, hydroxyl, and peroxide radicals. These chemicals are also
used by the immune system as ’weapons’ to destroy items recog-
nised as foreign to the human body (Smith 1988). It is believed
that immunosuppressivemethodswill prevent the immune system
from producing such chemicals thereby reducing damage. At the
same time, the immunosuppressive agents are intended to halt the
progress of fibrosis, which is a part of immune reaction (Jaeschke
1997).
Why it is important to do this review
Though it has been inferred from experiment (Lee 1984) and clin-
ical experience (Agarwal 2006) that immunosuppressive therapy
might reduce deaths in paraquat poisoned patients, there has been
no conclusion on the effectiveness of this treatment. Considering
the hazards associated with immunosuppressive drugs (Winsett
2004), for example by making patients more prone to infection
in the long term, it is timely to have a systematic review on this
topic to support decision-making or suggest further research.
O B J E C T I V E S
To assess the effects of glucocorticoid with cyclophosphamide on
mortality in patients with paraquat-induced lung fibrosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) were included.
Types of participants
Any person with paraquat poisoning.
3Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of interventions
All patients were to receive standard care plus either the interven-
tion or control.
• Intervention: Glucocorticoid with cyclophosphamide in
combination.
• Control: Placebo, standard care alone, or any other therapy
in addition to standard care.
Studies that focused on any single immunosuppressant or other
combinations of therapies were excluded.
Types of outcome measures
• Mortality at 30 days following the ingestion of paraquat.
• All-cause mortality at the end of the follow-up period.
Search methods for identification of studies
The search was not restricted by date, language or publication
status.
Electronic searches
Electronic searches were carried out in both English and Chinese
databases.
We searched the following English language databases;
• Cochrane Injuries Group’s Specialised Register (searched 15
Sept 2009),
• CENTRAL (The Cochrane Library 2009, Issue 3),
• MEDLINE (Ovid SP) 1950 September Week 1 2009,
• EMBASE (Ovid SP) 1980 to 2009 Week 37,
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) 1970 to Sept 2009,
• ISI Web of Science: Conference Proceedings Citation
Index- Science (CPCI-S) 1990 to Sept 2009.
The search strategies are reported in full in Appendix 3.
We searched the following Chinese language databases using the
search strategy reported in Appendix 2, (which is a modified and
translated version of the strategy formulated by the Cochrane In-
juries Group’s Trials Search Coordinator in Appendix 1);
• Chinese bio-medical literature & retrieval system (CBM)
(1978-September 2009),
• Chinese medical current contents (CMCC) (1995-
September 2009),
• Chinese medical academic conference (CMAC) (1994-
September 2009).
Due to the paucity of trials in this area, we did not restrict our
search by using a filter to identify only RCTs.We sought all types of
trials in the hope we might identify RCTs that may have otherwise
been overlooked.
We searched the following two trial registers using the term
’paraquat’:
• Clinicaltrials.gov,
• Controlled-trials.com.
Searching other resources
We searched the Internet through search engines Google.com and
Baidu.com, using the term ’clinical trial & paraquat’. We also
checked the reference lists of reports and literature reviews on
paraquat poisoning for potentially relevant published or unpub-
lished trials. We contacted the authors of the included trials for
further information.
Data collection and analysis
Selection of studies
The search results from English language databases were screened
independently by LL and BC. The results from the Chinese
databases were screened independently by LL and YC. The full
text versions of potentially relevant trials were obtained and as-
sessed. Duplicate reports were identified and noted. LL and BC
disagreed about the inclusion of the Afzali 2008 study due to the
use of alternation as the method of randomisation. YC moderated
the discussion on inclusion of this trial, and it was agreed that the
trial would be included but noted as being of high risk of bias.
Data extraction and management
Data from the three included trials were extracted independently
by LL, BC and ES. Data were extracted on the study design, num-
ber of participants in the intervention and control groups, the
number of deaths in each group on an intention-to-treat basis,
and loss to follow-up in each trial. Information on the methodol-
ogy of each trial was recorded for assessment of the risk of bias, as
described below. Data were analysed using Review Manager soft-
ware.
Assessment of risk of bias in included studies
Three authors (LL, BC and ES) independently evaluated the risk
of bias for each included trial in the following domains: sequence
generation, allocation concealment, blinding, incomplete report-
ing, selective outcome reporting and any other sources of bias.
To facilitate a valid judgement, we wrote to the contact person
for each trial to request further information. Our judgement was
made according to the criteria defined by (Higgins 2008), where
’Yes’ means low risk of bias, ’Unclear’ means not enough informa-
tion was provided to make a judgement, and ’No’ means there is
potential for high risk of bias. The judgements can be found in
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the risk of bias tables below, and a summary of the judgements are
in Figure 1 and 2.
Measures of treatment effect
The risk ratio (RR) and 95% confidence interval (CI) was calcu-
lated for each trial on an intention-to-treat basis. Data for all-cause
mortality at final follow-up were summarised in a meta-analysis
using a fixed-effects model.
Dealing with missing data
The amount of loss to follow-up in each trial was assessed.
Assessment of heterogeneity
Clinical heterogeneity was assessed by considering the design of
each trial. Where suspicion of clinical heterogeneity arose, the
differences in study design among trials was considered.
Where possible and appropriate, the statistical heterogeneity was
examined using the Chi2 test. A p-value below 0.10 indicated
heterogeneity but was interpretedwith caution. The I² statistic was
calculated to assess the attribution of heterogeneity to the diversity
of results from different trials.
Assessment of reporting biases
Due to the small number of trials included in the review, we did
not investigate reporting bias through a funnel plot.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The electronic searches for studies retrieved 576 records. Of these
records 506 were excluded due to irrelevance to paraquat or dupli-
cation. From the remaining 70 studies, we identified 3 randomised
controlled trials.
LL identified 768 reports through a Chinese language search on
Chinese language databases; none of them met the inclusion cri-
teria.
LL identified one ongoing RCT which is described in the ’Char-
acteristics of ongoing studies’ section below.
LL identified one report while searching Google.com using the
term ’clinical trial & paraquat’ which was later excluded (Tsai
2009). No additional eligible randomised trials were identified
through screening reference lists or literature reviews.
Included studies
Three trials with a combined total of 164 participants are in-
cluded in this review (Afzali 2008, Lin 1999, Lin 2006). All three
compared the use of standard care alone versus standard care and
glucocorticoid with cyclophosphamide for patients with paraquat
poisoning. Mortality at final follow-up was the primary outcome
in all three trials.
All three trials included moderate to severely paraquat poisoned
patients who had a urine sodium dithionite test reaction of dark
blue or navy blue. The Lin 2006 trial had an additional inclusion
criteria of a predicted mortality of >50% and ≤90% according to
the Hart 1984 formula. (Readers of the review should therefore
bear in mind that the trials included in the review had slightly
different inclusion criteria and should interpret the findings of the
review accordingly.) Patients with mild paraquat poisoning were
not included in any trial.
Excluded studies
Two trials were excluded: in one trial the intervention was methyl-
prednisolone only (Tsai 2009), and the other was a historical con-
trolled trial (Perriens 1992).
Risk of bias in included studies
The trial by Lin 2006 had a relatively low risk of bias. The trial
by Lin 1999 randomised all urine positive patients but presented
the outcomes for those who died within one week of poisoning
separately from those who survived longer. Presenting the data
separately is reasonable to a certain extent given the specific clinical
features of paraquat poisoning, but also suggests reporting bias.
The exact methods used for patient selection, randomisation, and
sequence concealment were not reported in the Afzali 2008 study
but we were able to gain the necessary details through contact with
the author and determined that the trial is at high risk of bias.
Our judgements of the risk of bias are recorded in the risk of bias
tables, and are displayed in Figure 1 and Figure 2.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies. Three studies are included in this review.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation
The Lin 2006 study used an appropriate method of sequence
generation and allocation concealment. Lin 1999 generated the
randomisation sequence using a random number table, but did
not conceal the sequence. Afzali 2008 used alternation with no
concealment, according to the author.
Blinding
None of the trials mentioned blinding of the treating physicians
or patients. In Lin 1999 and Lin 2006 the statistician who con-
tributed to the trial report was blinded to the allocation.
Incomplete outcome data
Mortality was the outcome of interest, and was reported in full in
all trials.
Selective reporting
There was no selective reporting of mortality. The Lin 1999 study
presented themortality data by severity of poisoning and randomi-
sation group which appears to have been a post-hoc decision in
the style of presenting results. However, we analysed the data ac-
cording to intention-to-treat which maintained the original ran-
domisation.
Other potential sources of bias
No other potential source of bias was found.
Effects of interventions
• All-cause mortality at the end of the follow-up period.
Analysis 1.1
All three trials reported death at the end of the follow-up period.
Patients who received glucocorticoid with cyclophosphamide in
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addition to standard care had a lower risk of death than those
receiving standard care alone (RR 0.72 (95% CI 0.59 to 0.89)).
There was some statistical heterogeneity between trials (Chi2=
5.96, df=2 (P=0.05); I2=66%).
• Mortality at 30 days following the ingestion of paraquat.
This outcome was not reported in any of the studies.
D I S C U S S I O N
Summary of main results
This systematic review includes three trials (one of low method-
ological quality) with a combined total of 164 participants who
had moderate to severe paraquat poisoning. Participants who re-
ceived glucocorticoid with cyclophosphamide in addition to stan-
dard care had a lower rate of death than those receiving standard
care alone.
Overall completeness and applicability of
evidence
There are few RCTs involving paraquat poisoned patients. The
review includes three small RCTs, one of which is of low quality.
A larger RCT is currently recruiting patients in Sri Lanka and data
from this study will be included in this review when available. To
enable further study of the effects of glucocorticoid and cyclophos-
phamide for paraquat poisoned patients, hospitals should provide
this treatment as part of an RCTwith allocation concealment. The
findings of this review should be interpreted with caution until
more data becomes available.
Potential biases in the review process
This review was conducted according to predefined inclusion cri-
teria and methodology to select and appraise eligible studies. The
search for trials was extensive, and was conducted on English and
Chinese language databases. Publication bias is a consideration in
any systematic review. Although there are only three small trials
included in this review, we believe that due to the extent of the
search for trials, these were the only RCTs addressing this research
question at the time of the search.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the findings of three small RCTs of moderate to severely
poisoned patients, glucocorticoid with cyclophosphamide in addi-
tion to standard care may be beneficial for patients with paraquat-
induced lung fibrosis. The finding of this review should be inter-
preted with caution until more data become available.
Implications for research
To enable further study of the effects of glucocorticoid with cyclo-
phosphamide for patients with moderate to severe paraquat poi-
soning, hospitals may provide this treatment as part of an RCT
with allocation concealment.
A C K N OW L E D G E M E N T S
We thank Karen Blackhall for providing the search strategy and
the search of English language databases.
R E F E R E N C E S
References to studies included in this review
Afzali 2008 {published data only}
Afzali S, Gholyaf M. The effectiveness of combined
treatment with methylprednisolone and cyclophosphamide
in oral paraquat poisoning. Archives of Iranian Medicine
2008;11(4):387–91.
Lin 1999 {published data only}
Lin JL, Leu ML, Liu YC, Chen GH. A prospective
clinical trial of pulse therapy with glucocorticoid and
cyclophosphamide in moderate to severe paraquat-poisoned
patients. American Journal of Respiratory and Critical Care
Medicine 1999;159:357–60.
Lin 2006 {published data only}
Lin JL, Lin-Tan DT, Chen KH, Huang WH. Repeated
pulse of methylprednisolone and cyclophosphamide with
continuous dexamethasone therapy for patients with severe
paraquat poisoning. Critical Care Medicine 2006;34(2):
368–73.
References to studies excluded from this review
Perriens 1992 {published data only}
Perriens JH, Benimadho S, Kiauw IL, Wisse J, Chee
H. High-dose cyclophosphamide and dexamethasone in
paraquat poisoning: a prospective study. Human and
Experimental Toxicology 1992;11(2):129–34.
Tsai 2009 {published data only}
Tsai J, Lee R, Wang C, Fang T, Hsu B. A clinical study of
prognosis and glucocorticoid pulse treatment in patients
8Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with acute paraquat intoxication. Tzu Chi Medical Journal
2009;21(2):156–60.
References to ongoing studies
Ariyananda 2006 {published data only}
A randomised controlled trial of high-dose
immunosuppression in paraquat poisoning.
(ISRCTN85372848). Ongoing study 30 August 2006.
Additional references
Agarwal 2006
Agarwal R, Srinivas R, Aggarwal AN, Gupta D. Experience
with paraquat poisoning in a respiratory intensive care unit
in North India. Singapore Medical Journal 2006;47(12):
1037.
Dinham 1996
Dinham B. Active ingredient fact sheet: Paraquat. PAN
UK: Pesticide News No. 32 2003:20–1.
Eddleston 2003
Eddleston M, Wilks MF, Buckley NA. Prospects
for treatment of paraquat-induced lung fibrosis with
immunosuppressive drugs and the need for better prediction
of outcome: a systematic review. QJM: An International
Journal of Medicine 2003;96:809–24.
Fukuda 1985
Fukuda Y, Ferrans VJ, Schoenberger CI, Rennard SI,
Crystal RG. Patterns of pulmonary structural remodeling
after experimental paraquat toxicity. The morphogenesis
of intraalveolar fibrosis. The American Journal of Medicine
1985;118(3):452–75.
Hart 1984
Hart TB, Nevitt A, Whitehead A. A new statistical approach
to the prognostic significance of plasma concentrations.
Lancet 1984;ii:1222–3.
Hettiarachchi 1989
Hettiarachchi J, Kodithuwakku GCS. Pattern of poisoning
in rural Sri Lanka. International Journal of Epidemiology
1989;18:418–22.
Higgins 2008
Higgins JPT, Green S. Cochrane Handbook for Systematic
Reviews of Interventions. Version 5.0.1 [updated September
2008]. The Cochrane Collaboration, 2008. Available from
www.cochrane–handbook.org.
Jaeschke 1997
Jaeschke H, Smith CW. Mechanisms of neutrophil-induced
parenchyma injury. Journal of Leukocyte Biology 1997;61:
647–53.
Koo 2002
Koo J, Kim J, Yoon J, Kim G, Jeon R, Kim H, Chae D,
Noh J. Failure of continuous venovenous hemofiltration to
prevent death in paraquat poisoning. American Journal of
Kidney Diseases 2002;39:55–9.
Lee 1984
Lee SS, Kawanami O, Aihara K, Chung CH, Hirohata
Y. Paraquat intoxication on rat lung. Korean Journal of
Pathology 1984;18(4):333.
Review Manager
The Nordic Cochrane Centre. Review Manager. 5.0.
Copenhagen: The Cochrane Collaboration, 2008.
Smith 1975
Smith P, Heath D. The pathology of the lung in paraquat
poisoning. Journal of Clinical Pathology 1975;9:81–93.
Smith 1988
Smith LL. The toxicity of paraquat. Adverse Drug Reactions
and Acute Poisoning Reviews 1988;1:1–17.
Suzuki 1993
Suzuki K, Takasu N, Okabe T, Ishimatsu S, Ueda A, Tanaka
S, Fukuda A, Arita S, Kohama A. Effect of aggressive
haemoperfusion on the clinical course of patients with
paraquat poisoning. Human and Experimental Toxicology
1993;12:323–7.
Tomlin 1994
Tomlin C. The Pesticide Manual. 10th Edition. Farnham
UK: British Crop Protection Council and the Royal Society
of Chemistry, 1994.
Wang 2008
Wang SY, Li YH, Chi GB, Xiao SY, Ozanne-Smith J,
Stevenson M, Phillips MR. Injury-related fatalities in
China: an under-recognised public-health problem.
www.thelancet.com Published online October 20, 2008.
[DOI: 10.1016/S0140-6736(08)61367-7]
WHO 2009
Word Health Organization. Poison information monograph
399. Paraquat. International programme for chemical
safety. March 26, 2009.
Winsett 2004
Winsett RP, Arheart K, Stratta RJ, Alloway R, Wicks
MN, Gaber AO, Hathaway DK. Evaluation of an
immunosuppressant side effect instrument. Progress in
Transplantation 2004;14(3):210-6, 240.
∗ Indicates the major publication for the study
9Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Afzali 2008
Methods Randomised controlled trial.
Participants Patients with moderate to severe paraquat poisoning. Poisoning was determined by a
navy blue or dark blue result of a urine sodium dithionite test
Interventions All patients received: ’...fixation of a nasogastric tube, gastric lavage with normal saline,
charcoal-sorbitol gavage every two to four hours for three days, forced alkalinised diuresis
in the first day of admission to the hospital, and haemodialysis of four hours duration
for both groups.’ p.388
The intervention group also received: ’...15 mg/kg of cyclophosphamide in dextrose
saline (200 mL) was infused in two hours for two days. Methylprednisolone, one gram
in 200 mL dextrose saline was also infused for four hours and was repeated for three
consecutive days. Meanwhile, 15 mg/kg of mesna was prescribed (for four days) in order
to avoid the side effects of cyclophosphamide.’ p.388
Outcomes Mortality.
Notes Recruitment was from September 2003 to October 2005.
Intervention group: 9 participants. 8 were male, 1 was female. Poisoning severity: 3 navy
blue, 6 dark blue
Control group: 11 participants. 8 were male, 3 were female. Poisoning severity: 4 navy
blue, 7 dark blue
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No We contacted the author of the study, who told us alter-
nation was used
Allocation concealment? No The study author told us there was no allocation con-
cealment
Blinding?
All outcomes
No Blinding was not reported and, according to the author,
was not done
Incomplete outcome data addressed?
All outcomes
Yes Themain outcome was death at final follow-up, and this
was reported in full
Free of selective reporting? Yes The study reported the main outcome, death at final
follow-up, in full
Free of other bias? Yes We did not identify any other areas of bias.
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Lin 1999
Methods Randomised controlled trial.
Participants People who had ingested paraquat within the previous 24 hours, and had a urine sample
which resulted in a navy blue or dark blue reaction to a sodium dithionite test
Interventions All patients received: ’To prevent absorption of paraquat from the gastrointestinal tract,
active charcoal added in magnesium citrate was given through a nasogastric tube after
gastric lavage with normal saline. All patients received two courses of 8-h active char-
coal haemoperfusion therapy in the emergency room (ER), and dexamethasone 10 mg
intravenous injection every 8 h was given for 14 d after admission.’ p.357
The intervention group also received: ’In addition, the study group patients received
pulse therapy after haemoperfusion at ER. Pulse therapy included 15 g/kg of CP in 5%
glucose saline 200 ml and 1 g MP in the other 200 ml 5% glucose saline intravenously
infused for 2 h/d. CP was infused for 2 d and MP for 3 d.’ p.357
(CP=cyclophosphamide; MP=methylprednisolone)
Outcomes Mortality.
Notes Recruitment was from January 1992 to December 1997.
Intervention Group: 56 participants. 33 were male, 23 were female
Control Group: 65 participants. 45 were male, 20 were female
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’...according to random digit methods.’ p.357
Allocation concealment? Unclear There was no mention of allocation concealment.
Blinding?
All outcomes
No Blinding of the treating physician and patients was not
reported
’At the end of this study, to avoid bias, the data were
collected and analysed by other doctors who were not
aware of the study.’ p.357
Incomplete outcome data addressed?
All outcomes
Yes Themain outcome was death at final follow-up, and this
was reported in full
Free of selective reporting? No Information on the primary outcome, mortality is pre-
sented in full. However, the study report authors present
the data according to severity of poisoning, although par-
ticipantswere randomised into the study regardless of the
severity of poisoning. We, the authors of this Cochrane
review, have combined the results from the two tables on
page 358 into the results of this review on an intention-
to-treat basis to maintain the study investigators’ origi-
nal randomisation
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Lin 1999 (Continued)
Free of other bias? Yes We did not identify any other areas of bias. The presen-
tation of results in the study report implies that the inter-
vention is effective in moderately poisoned patients; but
we have used an intention-to-treat analysis to summarise
the findings in this review which corrects this potential
bias
Lin 2006
Methods Randomized controlled trial.
Participants Patients who: 1) arrived at the emergency room within 24 hours of ingesting paraquat,
2) were age 15 years or older, 3) had predicted mortality of >50% and ≤90% according
to the Hart 1984 formula, and 4) had urine sodium dithionite tests showing the colour
dark blue or navy blue.
The exclusion criteria were: ’Patients were excluded from the study if they had dermal
exposure to paraquat; received intravascular injection of paraquat; did not have paraquat
levels in biological fluids; arrived at the emergency room >24 hours after ingestion of
paraquat; ingested paraquat due to major systemic diseases including cancer and heart,
lung, renal, and liver diseases; or did not give informed consent.’ p.369
Interventions All patients received: ’To prevent absorption of paraquat from the gastrointestinal tract,
activated charcoal 1 g/kg added to 250 mL of magnesium citrate was given through a
nasogastric tube after gastric lavage with normal saline. In addition, all patients received
two doses of 8-hr active charcoal-containing haemoperfusion therapy in the emergency
room.’ p.369
The control group received: ’After haemoperfusion therapy, the control group received
dexamethasone 5 mg in an intravenous injection every 6 hrs until their arterial blood
gas showed PaO2 11.5 kPa (80mm Hg) or they died.’ p.369
The intervention group received: ’At the same time, the study group received pulse
therapy with 15 mg/kg cyclophosphamide in 5% glucose saline 200 mL and 1 g of
methylprednisolone in the other 200 mL of 5% glucose saline intravenously infused for
2 hrs per day. Cyclophosphamide was infused for 2 days and methylprednisolone for 3
day simultaneously. Preceding dexamethasone, a 5-mg intravenous injection every 6 hrs
was given until the arterial blood gas showed PaO2 11.5 kPa (80 mm Hg). Repeated
pulse therapy with 1 g of methylprednisolone in the other 200 mL of 5% glucose saline
intravenously infused for 2 hrs per day for 3 days was given again if PaO2 was 8.64
kPa (60 mm Hg). In addition, 15mg/kg/day cyclophosphamide was infused for 1 day
again if patients’ white cell counts were 3000/m3 and the duration was 2 wks after initial
cyclophosphamide pulse therapy to avoid a severe leukopenia episode.’ p.369
Outcomes Mortality.
Notes Participants were followed up for six weeks.
Recruitment was from January 1999 to December 2003.
Intervention Group: 16 participants. 11 were male, 5 were female. Poisoning severity: 5
navy blue, 11 dark blue
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Lin 2006 (Continued)
Control Group: 7 participants. 5 were male, 2 were female. Poisoning severity: 1 navy
blue, 6 dark blue
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’All study patients were randomly allocated to control
and study groups in the proportion of 1:2 by means of a
sequence of labelled cards contained in sealed numbered
envelopes that were prepared by a statistical adviser.’ p.
369
Allocation concealment? Yes ’...(the envelope was) opened by the researcher in the
presence of patients.’ p.369
Blinding?
All outcomes
No ’Neither stratification nor blinding was made in this
study.’ p.369 ’The data were collected and analysed by
other doctors not familiar with the study.’ p.369
Incomplete outcome data addressed?
All outcomes
Yes Themain outcome was death at final follow-up, and this
was reported in full
Free of selective reporting? Yes The study reported the main outcome, death at final
follow-up, in full
Free of other bias? Yes Wedidnot identify any other areas of bias. The inclusion
criterion, using theHart 1984 predictive mortality scale,
was the main area for bias in this study (i.e. patients with
a predicted mortality of ≥90% or <50% were excluded
from the trial)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Perriens 1992 It was a historically controlled study, not randomised. ’Patients admitted before October 10, 1986 received the
standard treatment only, because i.v. cyclophosphamide and i.v. dexamethasone were not available in Suriname until
that time. Patients presenting after October 10, 1986 received high-dose cyclophosphamide and dexamethasone
treatment, in addition to standard treatment.’ p130
Tsai 2009 This study focused on methylprednisolone only.
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Characteristics of ongoing studies [ordered by study ID]
Ariyananda 2006
Trial name or title A randomised controlled trial of high-dose immunosuppression in paraquat poisoning. (ISRCTN85372848)
Methods Randomised controlled trial.
Participants Patients with paraquat poisoning.
Sample size: 600 (300 active, 300 placebo)
Interventions Intervention: Two days of cyclophosphamide 750 mg (if weight is less than 50 kg) or one gram (if weight
is more than 50 kg), and three days of methylprednisolone one gram both by intravenous infusion over one
hour. Steroids in the form of oral dexamethasone (8 mg three times daily) will be continued for the next two
weeks. Patients will receive mesna 400 mg intravenous at start of therapy and four and eight hours later to
reduce risk of haemorrhagic cystitis
Control: Control patients will receive saline placebo infusion and placebo capsules
Outcomes Primary: All-cause mortality in hospital.
Secondary: 1. All-cause mortality at three months post-ingestion. 2. Lung function in survivors at three
months
Starting date 30 August 2006
Contact information Contact person: Pilane Liyanage Ariyananda
South Asian Clinical Toxicology Research Collaboration (SACTRC) (Sri Lanka)
SACTRC Department of Medicine University of Peradeniya
20000
Peradeniya
Sri Lanka
+94 (0)81 238 4556
ariyananda@sltnet.lk
Notes Sponsors: 1. Syngenta Crop Protection AG (USA) 2. The Wellcome Trust (UK) (Grant reference number:
071669)
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D A T A A N D A N A L Y S E S
Comparison 1. All-cause mortality at final follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality at final
follow-up
3 164 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.59, 0.89]
Analysis 1.1. Comparison 1 All-cause mortality at final follow-up, Outcome 1 All-cause mortality at final
follow-up.
Review: Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis
Comparison: 1 All-cause mortality at final follow-up
Outcome: 1 All-cause mortality at final follow-up
Study or subgroup Favours intervention Favours control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Afzali 2008 3/9 9/11 12.4 % 0.41 [ 0.16, 1.07 ]
Lin 1999 38/56 53/65 74.9 % 0.83 [ 0.67, 1.03 ]
Lin 2006 5/16 6/7 12.7 % 0.36 [ 0.17, 0.80 ]
Total (95% CI) 81 83 100.0 % 0.72 [ 0.59, 0.89 ]
Total events: 46 (Favours intervention), 68 (Favours control)
Heterogeneity: Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 3.11 (P = 0.0019)
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours control
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Ovid MEDLINE(R) 1950 to July Week 1 2009. This strategy was formulated by the Cochrane Injuries Group’s Trials Search
Coordinator. It was then translated and adapted for use in Chinese language databases by review author Luying Ryan Lee.
1.exp Herbicides/
2.exp Paraquat/
3.(Paraquat or (methyl adj3 viologen) or gramoxone or paragreen or Herbicide* or Pyridinium Compound*).mp.
4.1 or 2 or 3
5.exp Lung Diseases/
6.exp Pulmonary Fibrosis/
7.((Pulmonary or lung) adj3 (fibrosis or fibroses)).ab,ti.
8.((Alveolitis or alveolitides) adj3 fibrosing).ab,ti.
9.5 or 6 or 7 or 8
10.exp Glucocorticoids/
11.glucocorticoid*.ab,ti.
12.exp Cyclophosphamide/
13.(Cyclophosphamide* or cytophosphan or cyclophosphane or procytox or sendoxan or b-518 or neosar or cytoxan or endoxan or
nsc-26271).ti,ab.
14.10 or 11 or 12 or 13
15.randomi?ed.ab,ti.
16.randomized controlled trial.pt.
17.controlled clinical trial.pt.
18.placebo.ab.
19.clinical trials as topic.sh.
20.randomly.ab.
21.trial.ti.
22.15 or 16 or 17 or 18 or 19 or 20 or 21
23.(animals not (humans and animals)).sh.
24.22 not 23
25.4 and 9 and 14 and 24
Appendix 2. Search strategy: Chinese language databases (English translation)
CBM (1978-September 2009), CMCC (1995-September 2009), CMAC (1994-September 2009)
1.exp herbicide/
2.exp paraquat/
3. 1 or 2
4.exp lung disease/
5.exp pulmonary fibrosis/
6.4 or 5
7.exp corticosteroids/
8.steroids*.ab,ti.
9.exp cyclophosphamide/
10.7 or 8 or 9 11.(randomised).ab,ti.
12.randomized controlled study.pt.
13.clinical controlled study.pt.
14.randomly.ab.
15.trail.ti.
16.11 or 12 or 13 or 14 or 15. 17.3 and 6 and 10and 16.
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Appendix 3. Search strategy: English language databases
Cochrane Injuries Group’s Specialised Register (searched 15 Sept 2009)
1.(Paraquat or (methyl and viologen) or Dimethyl* or gramoxone or grammoxone or paragreen or Herbicide* or “Pyridinium com-
pound” or pathclear or weedol)
2.(cyclophosphamid* or carloxan or clafen or cycloblastin or cycloblastine or “cyclofos amide” or cyclofosfamid or cyclofosfamide or
cyclophosphan* or cycloxan or cyphos or cytophosphan* or cytoxan or “endocyclo phosphate” or endoxan* or enduxan or “genoxalor
mitoxan” or neosan or neosar or noristan or “nsc 26271” or “nsc 2671” or b-51
3.1 and 2
CENTRAL (The Cochrane Library 2009, Issue 3)
#1MeSH descriptor Herbicides explode all trees
#2MeSH descriptor Paraquat explode all trees
#3(Paraquat or (methyl near3 viologen) or Dimethyl* or gramoxone or grammoxone or paragreen or Herbicide* or Pyridinium
compound* or pathclear or weedol)
#4 (#1 OR #2 OR #3)
#5MeSH descriptor Glucocorticoids explode all trees
#6MeSH descriptor Cyclophosphamide explode all trees
#7(cyclophosphamid* or carloxan or clafen or cycloblastin or cycloblastine or cyclofos amide or cyclofosfamid or cyclofosfamide or
cyclophosphan*or cycloxan or cyphos or cytophosphan* or cytoxan or endocyclo phosphate or endoxan* or enduxan or genoxalor
mitoxan or neosan or neosar or noristan or nsc 26271 or nsc 2671 or b-518 or procytox* or semdoxan or sendoxan)
#8 (#5 OR #6 OR #7)
#9(#4 AND #8)
MEDLINE (Ovid SP) 1950 September Week 1 2009
1.exp Herbicides/
2.exp Paraquat/
3.(Paraquat or (methyl adj3 viologen) orDimethyl* or gramoxone or grammoxone or paragreen orHerbicide* or Pyridiniumcompound*
or pathclear or weedol).mp.
4.1 or 2 or 3
5.exp Lung Diseases/
6.exp Pulmonary Fibrosis/
7.((Pulmonary or lung) adj3 (fibrosis or fibroses)).ab,ti.
8.((Alveolitis or alveolitides) adj3 fibrosing).ab,ti.
9.5 or 6 or 7 or 8
10.exp Glucocorticoids/
11.glucocorticoid*.ab,ti.
12.exp Cyclophosphamide/
13.(cyclophosphamid* or carloxan or clafen or cycloblastin or cycloblastine or cyclofos amide or cyclofosfamid or cyclofosfamide or
cyclophosphan*or cycloxan or cyphos or cytophosphan* or cytoxan or endocyclo phosphate or endoxan* or enduxan or genoxalor
mitoxan or neosan or neosar or noristan or nsc 26271 or nsc 2671 or b-518 or procytox* or semdoxan or sendoxan).ab,ti.
14.10 or 11 or 12 or 13
15.4 and 9 and 14
16.(animals not (humans and animals)).sh.
17.15 not 16
EMBASE (Ovid SP) 1980 to 2009 Week 37
1.exp Herbicide/
2.exp Paraquat/
3.exp pyridinium derivative/
4.(Paraquat or (methyl adj3 viologen) orDimethyl* or gramoxone or grammoxone or paragreen orHerbicide* or Pyridiniumcompound*
or pathclear or weedol).mp.
5.1 or 2 or 3 or 4
6.exp Lung Disease/
7.exp lung fibrosis/
8.((Pulmonary or lung) adj3 (fibrosis or fibroses)).ab,ti.
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9.((Alveolitis or alveolitides) adj3 fibrosing).ab,ti.
10.6 or 7 or 8 or 9
11.exp Glucocorticoids/
12.glucocorticoid*.ab,ti.
13.exp Cyclophosphamide/
14.exp cyclophosphamide derivative/
15.(cyclophosphamid* or carloxan or clafen or cycloblastin or cycloblastine or cyclofos amide or cyclofosfamid or cyclofosfamide or
cyclophosphan*or cycloxan or cyphos or cytophosphan* or cytoxan or endocyclo phosphate or endoxan* or enduxan or genoxalor
mitoxan or neosan or neosar or noristan or nsc 26271 or nsc 2671 or b-518 or procytox* or semdoxan or sendoxan).ab,ti.
16.11 or 12 or 13 or 14 or 15
17.5 and 10 and 16
18.exp animal/ not (exp human/ and exp animal/)
19.17 not 18
ISIWeb of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to Sept 2009 and ISIWeb of Science: Conference
Proceedings Citation Index-Science (CPCI-S) 1990 to Sept 2009
1.(Paraquat or or Dimethyl* or gramoxone or grammoxone or paragreen or Herbicide* or or pathclear or weedol or Pyridinium
compound*) or (methyl same viologen)
2.(cyclophosphamid* or carloxan or clafen or cycloblastin or cycloblastine or cyclofos amide or cyclofosfamid or cyclofosfamide or
cyclophosphan*or cycloxan or cyphos or cytophosphan* or cytoxan or endocyclo phosphate or endoxan* or enduxan or genoxalor
mitoxan or neosan or neosar or noristan or nsc 26271 or nsc 2671 or b-518 or procytox* or semdoxan or sendoxan)
3.((Pulmonary or lung) SAME (fibrosis or fibroses)) OR ((Alveolitis or alveolitides) SAME fibrosing) OR (lung* SAME disease*)
4.1 and 2 and 3
H I S T O R Y
Protocol first published: Issue 4, 2009
Review first published: Issue 6, 2010
C O N T R I B U T I O N S O F A U T H O R S
Luying Ryan Li (LL) and Chao You (CY) were responsible for writing the protocol. Bhuwan Chaudhary (BC) and LL selected the
trials from English language databases. LL and YC selected trials from Chinese language databases. YC offered interpretation of the
clinical features of paraquat poisoning and arbitrated on the inclusion of one trial (Afzali 2008). Emma Sydenham (ES), LL and
BC independently assessed the risk of bias in the included trials and extracted data. LL and ES interpreted the data and wrote the
manuscript. All authors agreed on the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We (LL and BC) were unable to hand search conference abstracts because our university library did not have any relevant abstracts in
the collection.
Emma Sydenham was added as an author.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cyclophosphamide [∗therapeutic use]; Drug Therapy, Combination [methods]; Glucocorticoids [∗therapeutic use]; Paraquat
[∗poisoning]; Pulmonary Fibrosis [chemically induced; ∗drug therapy; immunology]; Randomized Controlled Trials as Topic
MeSH check words
Humans
19Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
